{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:50:50Z","timestamp":1788587450169,"version":"build-2803163510"},"reference-count":51,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UroToday Publishing, EAU"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.2217\/fon-2019-0817","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T07:09:51Z","timestamp":1583996991000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":86,"title":["KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC"],"prefix":"10.1080","volume":"16","author":[{"given":"Ashish M","family":"Kamat","sequence":"first","affiliation":[{"name":"Department of Urology,The University of Texas MD Anderson Cancer Center,\rHouston,\rTX\r77030,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[{"name":"Department of Urology,Carolina Urologic Research Center,\rMyrtle Beach,\rSC\r29572,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Oncology & Department of Urology,Johns Hopkins University School of Medicine,\rBaltimore,\rMD\r21287,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Alanee","sequence":"additional","affiliation":[{"name":"Department of Urology,Henry Ford Hospital,\rDetroit,\rMI\r48202,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology,University of Tsukuba,\rTsukuba\r305-8577,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh","family":"Shariat","sequence":"additional","affiliation":[{"name":"Department of Urology,Medical University of Vienna,\r1090\rVienna,\rAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kijoeng","family":"Nam","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Research Decision Sciences, Merck & Co.,Inc.,\rKenilworth,\rNJ\r07033,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Kapadia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Merck & Co.,Inc.,\rKenilworth,\rNJ\r07033,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Frenkl","sequence":"additional","affiliation":[{"name":"Department of Oncology, Merck & Co.,Inc.,\rKenilworth,\rNJ\r07033,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Urology,NYU Langone Health,\rNew York,\rNY\r10017,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"National Cancer Institute\n. SEER cancer stat facts: bladder cancer (2019). https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12468"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","unstructured":"NICE Guidance\n. Bladder cancer: diagnosis and management of bladder cancer. BJU Int.120(6) 755\u2013765 (2017).","DOI":"10.1111\/bju.14045"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_3_4_8_1","article-title":"NCCN clinical practice guidelines in oncology","author":"National Comprehensive Cancer Network","unstructured":"National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology. Bladder Cancer (2019). www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf","journal-title":"Bladder Cancer"},{"key":"e_1_3_4_9_1","unstructured":"BCG live (for intravesical use) TICE\u00ae BCG [package insert]. Organon USA NJ USA (2009). www.fda.gov\/media\/76396\/download"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67280-1"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.11.005"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.02.020"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13410"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012006"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.045"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6901"},{"key":"e_1_3_4_20_1","first-page":"301","article-title":"Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumor upstaging at radical cystectomy","volume":"95","author":"Wiesner C","year":"2004","unstructured":"Wiesner C , PfitzenmaierJ, FaldumA. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumor upstaging at radical cystectomy. Urol. Oncol.95, 301\u2013305 (2004).","journal-title":"Urol. Oncol."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.01.025"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.08.015"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2550-x"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14502"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0000000000000606"},{"issue":"7","key":"e_1_3_4_26_1","first-page":"423","article-title":"Failure of Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder cancer: definition and treatment options","volume":"69","author":"Gual Frau J","year":"2016","unstructured":"Gual Frau J , PalouJ, RodriguezO, ParadaR, BredaA, VillavicencioH. Failure of Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder cancer: definition and treatment options. Arch. Esp. Urol.69(7), 423\u2013433 (2016).","journal-title":"Arch. Esp. Urol."},{"issue":"1","key":"e_1_3_4_27_1","first-page":"CD011935","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","author":"Schmidt S","year":"2020","unstructured":"Schmidt S , KunathF, ColesBet al. Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst. Rev.1, CD011935 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000273461"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00260"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287214541798"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00121"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03421-5"},{"key":"e_1_3_4_33_1","first-page":"CD012112","article-title":"Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd AR","year":"2017","unstructured":"Shepherd AR , ShepherdE, BrookNR. Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst. Rev.3, CD012112 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1497-0"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.09.06"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0084-z"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.08.111"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.12.031"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135157"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0731"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22588"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6498-2"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26122"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0266-z"},{"key":"e_1_3_4_46_1","volume-title":"KEYTRUDA\u00ae (Pembrolizumab) for injection, for intravenous use","year":"2020","unstructured":"KEYTRUDA\u00ae (Pembrolizumab) for injection, for intravenous use. Merck Sharp & Dohme Corp., NJ, USA (2020). www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz127"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4524"},{"issue":"5","key":"e_1_3_4_51_1","first-page":"v356","article-title":"Health-related quality of life and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab for patients with high-risk non\u2013muscle invasive bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin","volume":"30","author":"De Wit R","year":"2019","unstructured":"De Wit R , KulkarniGS, UchioEMet al. Health-related quality of life and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab for patients with high-risk non\u2013muscle invasive bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin. Ann. Oncol.30(Suppl. 5), v356\u2013v402 (2019).","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_52_1","volume-title":"Phase I trial of intravesical Bacillus Calamette-Gu\u00e9rin combined with intravenous pembrolizuamb in high-grade nonmuscle invasive bladder cancer.","author":"Alanee S","year":"2019","unstructured":"Alanee S , El-ZawahryA, McVaryKet al. Phase I trial of intravesical Bacillus Calamette-Gu\u00e9rin combined with intravenous pembrolizuamb in high-grade nonmuscle invasive bladder cancer. Presented at: 20th Annual Meeting of the Society of Urologic Oncology. Washington DC, WA, USA, 4\u20136 December 2019."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:46:10Z","timestamp":1719110770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.2217\/fon-2019-0817"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0817","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}